vs
Side-by-side financial comparison of NETSTREIT Corp. (NTST) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $57.1M, roughly 1.0× NETSTREIT Corp.). NETSTREIT Corp. runs the higher net margin — 10.0% vs -83.0%, a 93.0% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 24.3%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 20.1%).
NETSTREIT Corp. is a US-headquartered real estate investment trust (REIT) that specializes in acquiring and operating a diversified portfolio of single-tenant net lease commercial properties. Its asset portfolio covers retail, industrial and office categories, primarily catering to investment-grade corporate tenants across the United States market.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
NTST vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.1M | $57.3M |
| Net Profit | $5.7M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 34.1% | -82.2% |
| Net Margin | 10.0% | -83.0% |
| Revenue YoY | 24.3% | 36.9% |
| Net Profit YoY | 235.9% | -9.6% |
| EPS (diluted) | $0.32 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $57.1M | — | ||
| Q4 25 | $52.5M | $57.3M | ||
| Q3 25 | $48.3M | $51.3M | ||
| Q2 25 | $48.3M | $48.5M | ||
| Q1 25 | $45.9M | $32.7M | ||
| Q4 24 | $44.1M | $41.8M | ||
| Q3 24 | $41.4M | $33.3M | ||
| Q2 24 | $39.6M | $29.1M |
| Q1 26 | $5.7M | — | ||
| Q4 25 | $1.3M | $-47.5M | ||
| Q3 25 | $618.0K | $-52.9M | ||
| Q2 25 | $3.3M | $-46.6M | ||
| Q1 25 | $1.7M | $-49.5M | ||
| Q4 24 | $-5.4M | $-43.3M | ||
| Q3 24 | $-5.3M | $-43.6M | ||
| Q2 24 | $-2.3M | $-32.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | 34.1% | — | ||
| Q4 25 | 2.6% | -82.2% | ||
| Q3 25 | 1.3% | -102.6% | ||
| Q2 25 | 6.8% | -93.4% | ||
| Q1 25 | 3.7% | -143.7% | ||
| Q4 24 | -12.3% | -98.6% | ||
| Q3 24 | -12.8% | -132.0% | ||
| Q2 24 | -5.8% | -139.2% |
| Q1 26 | 10.0% | — | ||
| Q4 25 | 2.5% | -83.0% | ||
| Q3 25 | 1.3% | -103.1% | ||
| Q2 25 | 6.8% | -96.1% | ||
| Q1 25 | 3.7% | -151.4% | ||
| Q4 24 | -12.3% | -103.6% | ||
| Q3 24 | -12.8% | -131.2% | ||
| Q2 24 | -5.8% | -110.9% |
| Q1 26 | $0.32 | — | ||
| Q4 25 | $0.01 | $-0.73 | ||
| Q3 25 | $0.01 | $-0.82 | ||
| Q2 25 | $0.04 | $-0.75 | ||
| Q1 25 | $0.02 | $-0.81 | ||
| Q4 24 | $-0.07 | $-0.71 | ||
| Q3 24 | $-0.07 | $-0.73 | ||
| Q2 24 | $-0.03 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.5B | $139.1M |
| Total Assets | $2.8B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $926.6M | — | ||
| Q1 25 | $913.3M | — | ||
| Q4 24 | $868.3M | — | ||
| Q3 24 | $778.7M | — | ||
| Q2 24 | $726.2M | — |
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.4B | $139.1M | ||
| Q3 25 | $1.3B | $148.8M | ||
| Q2 25 | $1.3B | $-11.9M | ||
| Q1 25 | $1.3B | $18.9M | ||
| Q4 24 | $1.3B | $21.7M | ||
| Q3 24 | $1.3B | $11.2M | ||
| Q2 24 | $1.3B | $39.3M |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.6B | $480.2M | ||
| Q3 25 | $2.5B | $506.9M | ||
| Q2 25 | $2.3B | $372.7M | ||
| Q1 25 | $2.3B | $386.7M | ||
| Q4 24 | $2.3B | $392.3M | ||
| Q3 24 | $2.2B | $363.6M | ||
| Q2 24 | $2.1B | $381.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.76× | — | ||
| Q3 25 | 0.84× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.65× | — | ||
| Q3 24 | 0.58× | — | ||
| Q2 24 | 0.55× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $109.5M | $-25.4M | ||
| Q3 25 | $28.0M | $-26.6M | ||
| Q2 25 | $30.6M | $-23.3M | ||
| Q1 25 | $22.1M | $-40.4M | ||
| Q4 24 | $90.2M | $-18.8M | ||
| Q3 24 | $25.1M | $-25.2M | ||
| Q2 24 | $25.4M | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | 82.46× | — | ||
| Q3 25 | 45.27× | — | ||
| Q2 25 | 9.36× | — | ||
| Q1 25 | 13.06× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTST
| Rental revenue (including reimbursable) | $54.0M | 95% |
| Other | $3.0M | 5% |
RYTM
Segment breakdown not available.
